Background: Demoralization has emerged as a distinct form of existential distress marked by pervasive feelings of hopelessness, loss of meaning/purpose, and a perceived failure to cope (1-4). While not an official diagnosis in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, it is included in the International Classification of Diseases 11th Edition (2). Prevalence rates range from 13–18% in patients with progressive illness (3) and 36-52% in patients with cancer (1,2). Still, demoralization is often misdiagnosed or overlooked (5). When left untreated, it is linked to increased symptom burden, decreased quality of life, and a desire for hastened death (1-3). Symptoms overlap with existential distress, anticipatory grief, moral injury, and major depressive disorder (MDD) (1,4,5). The process of differentiating demoralization from MDD is particularly nuanced (1,2,5). This Fast Fact aims to distinguish demoralization from MDD and highlight unique treatment considerations.  

Demoralization vs. clinical depression: While both demoralization and MDD involve depressed mood, demoralization is usually attributable to a single precipitating factor: the underlying serious illness itself (6). Demoralization symptoms are often in response to disruptions of functional capacity and ability to meaningfully engage in life brought on by the underlying illness. As compared to MDD, with its defining feature of generalized anhedonia (a loss of interest in and pleasure from current activities one previously enjoyed) (1,7), demoralization is marked by an anticipatory loss of enjoyment in future activities given illness-related symptoms and barriers (3,7). Unlike anhedonia, individuals with demoralization often remain interested in activities and feel joy in the present moment. Other core features of demoralization are a loss of meaning/purpose and perceived failure to cope, which is distinct from the generalized worthlessness seen in MDD (2). MDD is typically marked by flat or constricted affect, while a fuller range of affect is common in demoralization (5). Both are linked with suicidality; however, demoralization often entails passive thoughts for a hastened death to alleviate suffering (1-3,5).

Risk factors for demoralization: living alone, unemployment, navigating a complex or expensive health system, prolonged hospitalizations, uncontrolled depression, anxiety, or pain.

Protective factors for demoralization: living with a partner, employment, positive perceptions of their social support, ability to find meaning or purpose in life.

Treatment considerations: Increased awareness is vital, as is managing distressing physical symptoms since they can contribute to demoralization. Additional management strategies include: 

• Medically ill patients with demoralization often develop a grounded sense that the potential burdens of life-prolonging interventions may outweigh the desired benefits. Providing transparent prognostic and anticipatory guidance may foster a patient’s sense of agency and reduce symptoms of demoralization. Consider a palliative care consultation to help with this.
• Mental health consultation may help for diagnostic clarification and tailored recommendations. While MDD has more physiologic components which can be targeted with medications, demoralization is typically less responsive to pharmaceuticals and more reliant on non-pharmacological interventions (5). Specific evidence-based psychotherapy approaches for demoralization aim to enhance adaptive coping skills and restore a sense of morale and purpose (7). They include (5,8):
  • Meaning-centered psychotherapy (promoting finding meaning and purpose in life).
  • Dignity therapy (reflecting on meaningful aspects of life and imparting wisdom to loved ones).
  • Narrative therapy (ascribing and reframing personal meaning).
  • Cognitive behavioral therapy (addressing negative cognitions and improving coping skills).
  • Interpersonal therapy (fostering connection and reducing social withdrawal).
• Consider contextual factors (multicultural, familial, spiritual) that may influence a patient’s beliefs about death/dying, feelings of hope and peace, and sense of meaning and purpose in life. Offer consultation for chaplaincy/spiritual care, as appropriate.
• While advancements in research are emerging, demoralization is not always “fixable.” This may elicit clinician discomfort and may even lead some clinicians to withdraw subtly from patients who are demoralized. Non-abandonment, reflective listening, and empathetic feedback are shown to be powerful clinical interventions for demoralization (9).

References: 

1. Clarke, D. M., Kissane, D. W., Trauer, T., et al. Demoralization, anhedonia and grief in patients with severe physical illness. World Psychiatry. 2005 Jun;4(2):96-105.
2. Fava, M., Sorg, E., Jacobs, J. M., et al. Distinguishing and treating demoralization syndrome in cancer: A review. General Hospital Psychiatry. 2023 Nov;85:185-90.
3. Robinson, S., Kissane, D.W., Brooker, J., et al. A systematic review of the demoralization syndrome in individuals with progressive disease and cancer: A decade of research. Journal of Pain Symptom Management. 2015 Mar;49(3):595-610.
4. Chopra, D. Academy of consultation-liaison psychiatry how to guide: Demoralization. 2022 Jan 24.
5. Strada, E. A. Grief, demoralization, and depression: Diagnostic challenges and treatment modalities. Primary Psychiatry. 2009 May 1;16(5):49.
6. Behan, D. Demoralization during medical illness: a case of common factors treatment. Clinical Social Work Journal. 2019 Sep 15;47(3):266-75.
7. Bovero, A., Opezzo, M., & Tesio, V. Relationship between demoralization and quality of life in end‐of‐life cancer patients. Psycho‐Oncology. 2023 Mar;32(3):429-37.
8. Dong, L., Li, L., Wu, Y., et al. A systematic review of interventions for demoralization in patients with chronic diseases. International Journal of Behavioral Medicine. 2024 Feb 5;1-10.
9. Sirri L, Fabbri S, Fava GA. New strategies in the assessment of psychological factors affecting medical conditions. Journal of Personality Assessment. 2007 Nov 14;89(3):216–28.

Authors’ Affiliations: University of Colorado School of Medicine, Denver, CO.
Conflicts of Interest:  The authors have no conflicts of interest to disclose.
Version History:  Originally edited by Sean Marks MD; first electronically published in May 2025.